
Free Daily Podcast Summary
by Ben Comer
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries.
The most recent episodes — sign up to get AI-powered summaries of each one.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided commu...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matte...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the lead...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, ...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also tal...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence. Simeon also discusses a new report published by SR One on how AI and China are changing the strategy and playbook for new drug creation. Access this and hundreds of epi...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign weal...
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why radiopharmaceutical companies live or die by manufacturing. Philina talks about AdvanCell's recent oversubscribed $315 million Series D raise, the company's vertically integrated manufacturing capability, and future plans for a regional U.S. man...
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

Biotech Hangout
A weekly discussion covering biotech news, data, deals, and regulatory updates featuring industry leaders and experts.

The Long Run with Luke Timmerman
In-depth conversations with biotech leaders navigating the challenges and opportunities of advancing science for human health.

Everybody's Business
A weekly look at business news from Wall Street to unusual ventures, with insights from Bloomberg Businessweek journalists.

KFF's The Business of Health with Chip Kahn
KFF

BiggerPockets Business Podcast
Real entrepreneurs share practical advice on starting, growing, and selling businesses, covering hiring, marketing, and raising capital.

Right About Now - Legendary Business Advice
Raw business insights from founders and industry leaders, revealing real wins, failures, and actionable strategies without the fluff.

Becker Business
Scott Becker

The Money Mondays
Business discussions on investments, side hustles, and entrepreneurship with experts, athletes, and influencers in personal settings.

Founder's Story
Raw conversations with entrepreneurs about the struggles, doubts, and pivotal moments behind their ventures.

The Prof G Pod with Scott Galloway
A no-holds-barred take on business, tech, culture, and life from a professor, author, and entrepreneur.

The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Analyzes the investment strategies of billionaire investors and explores lessons from legendary financiers on wealth, wisdom, and life.

Mind The Business: Small Business Success Stories
Small business owners share real stories about starting, growing, and navigating the challenges of entrepreneurship.
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Business Of Biotech in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Business Of Biotech as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Ben Comer.
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
Business Of Biotech publishes weekly. Our AI generates a summary within hours of each new episode.
Business Of Biotech covers topics including Science, Business, Management, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.